



Curriculum Vitae

Personal information Asimina Zisi

Work experience

1. Employer: Swedish Medical Products Agency
 - Start date: 022023
 - End date:
 - Position: Assessor
 - Activities: Clinical Assessor in the fields of Oncology, Hematology and Dermatology
 - Country: Sweden
2. Employer: Karolinska Institutet
 - Start date: 102022
 - End date: 012023
 - Position: Post_doctoral Researcher
 - Activities: Worked with drug repurposing candidates for cancer therapy, characterizing new mechanistic implications.
 - Country: Sweden

Education and training

1. Subject: Karolinska Institute
 - Start date: 092017
 - End date: 102022
 - Qualification: Ph.D. in Medicine
 - Organisation: Investigated Ribosome Biogenesis as a molecular target for cancer therapy, leading to the discovery, design and/or characterization of small_molecule inhibitors, identifying susceptible cancer types such as Glioblastoma, and detecting combinatorial treatments with Receptor Tyrosine Kinase Inhibitors to prevent resistance development. Other projects included the identification of unexplored and druggable enzymatic targets important for cancer cell growth, as well as the study of cancer treatments focused on the p53_MDM2 axis. Thesis: RNA Polymerase I Inhibition: Mechanism and Exploitation in Cancer Treatment
 - Country: Sweden
2. Subject: Uppsala University
 - Start date: 082015
 - End date: 052017
 - Qualification: Master of Science in Medical Research
 - Organisation: Subject: Infection and Cancer Biology, Drug Design and Development
 - Country: Sweden
3. Subject: Aristotle University of Thessaloniki
 - Start date: 092010
 - End date: 062015
 - Qualification: Diploma in Pharmacy (PharmD)
 - Organisation: Performed research on cutaneous antiseptics and antibiotic_loaded dressings for wound healing applications.
 - Country: Greece

Additional information

Publications

A. Zisi, D.C. Kanellis, S. Moussaud, et al. (2022) Small molecule_mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth, *Neuro_Oncology*, noac286. DOI: 10.1093/neuonc/noac286 A. Zisi, J. Bartek, M.S. Linström. (2022) Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward. *Cancers*, 14, 2126. DOI: 10.3390/cancers14092126 D.C. Kanellis, J.A. Espinoza, A. Zisi, et al. (2021) The exon_junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. *Science Advances*. 7(32):eabf7561. DOI: 10.1126/sciadv.abf7561 J.A. Espinoza, A. Zisi, D.C. Kanellis, et al. (2020) The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy_inhibitory activity. *Cell Death Differ* 27, 773–789. DOI: 10.1038/s41418_019_0387_5 P. Sifaka, A. Zisi, M. Exindari, et al. (2016) Porous dressings of modified chitosan with poly(2_hydroxyethyl acrylate) for topical wound delivery of levofloxacin. *Carbohydrate Polymers*, 143, 90_99. DOI: 10.1016/j.carbpol.2016.02.009 A. Zisi, M. Exindari, E. Siska, G. Koliakos. (2018) Iodine_lithium_alpha_dextrin (ILaD) against *Staphylococcus aureus* skin infections: a comparative study of in_vitro bactericidal activity and cytotoxicity between ILaD and povidone_iodine. *Journal of Hospital Infection*, 98(2), 134_140. DOI: 10.1016/j.jhin.2017.07.013.

Projects

Memberships

Other Relevant Information